Chicago, Illinois 60612


Purpose:

To compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries.


Study summary:

Anatomic and reverse total shoulder arthroplasty (TSA) is associated with the risk of moderate to significant blood loss that can lead to transfusions. Average estimated blood loss has been reported in the range of 354 to 361 mL intraoperatively, not accounting for additional postoperative blood loss postoperatively in surgical drains. Transfusion rates have been reported to range from 2.4% to 9.5% in recent studies, with rates over 30% for revision cases. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that is an established method of reducing blood loss and transfusion requirement for patients undergoing total hip and knee arthroplasty. TXA can be administered intravenously, topically (intraarticularly), or orally, with most available literature addressing intravenous and topical administration. Systematic reviews and meta-analyses of the total hip and knee arthroplasty literature demonstrate approximately a 30% decrease in blood loss and 50% decrease in transfusion rate with topical or intravenous administration of TXA compared to placebo. Moreover, the literature demonstrates no increased rate of thromboembolic or other complications associated with TXA administration for hip and knee arthroplasty. Despite proven efficacy in the hip and knee arthroplasty literature, there have been no studies analyzing the ability of TXA to reduce blood loss and transfusion rate following TSA. Purpose of the study is to compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries. With the hypothesis that intravenous TXA will reduce blood loss following TSA.


Criteria:

Inclusion Criteria: - Any patient scheduled for a primary anatomic or reverse TSA Exclusion Criteria: - Allergy to TXA - Acquired disturbances of color vision - Pre-op use of anticoagulant therapy within five days before surgery - History of arterial or venous thromboembolic disease; such as DVT, PE, CVA, TIA - Pregnancy or breastfeeding - Recent MI (within 6 months of surgery) or any placement of stent regardless of time since placement - Renal impairment - Refusal of blood products - Any patient undergoing a revision TSA - Patients who decline to participate


NCT ID:

NCT02569658


Primary Contact:

Principal Investigator
Yale A Fillingham, MD
Rush University Medical Center

Yale A Fillingham, MD
Phone: 312-942-6000 ext. 3384
Email: yale_fillingham@rush.edu


Backup Contact:

N/A


Location Contact:

Chicago, Illinois 60612
United States

Yale A Fillingham, MD
Phone: 312-942-6000
Email: yale_fillingham@rush.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.